NEW YORK, May 11, 2026, 05:10 EDT
- Moderna’s early-stage push on a hantavirus vaccine is back in the spotlight following a fatal outbreak linked to the MV Hondius cruise ship.
- Health agencies logged six confirmed cases, two described as probable, and three fatalities, but continue to assess the risk to the wider public as low.
- Moderna finished Friday up almost 12%. At the time of this dateline, the Nasdaq’s regular hours hadn’t started yet.
Moderna Inc.’s early-stage hantavirus vaccine programs drew renewed attention Monday after the MV Hondius, a luxury cruise ship, was struck by a fatal Andes virus outbreak—one form of hantavirus known for causing serious lung complications. Countries scrambled to bring home their citizens from the vessel.
The outbreak’s timing is crucial—it’s thrust a niche, mostly academic vaccine project into the market limelight right when Moderna is under pressure to show it can generate sales outside its COVID vaccine. Messenger RNA technology, or mRNA, works by telling cells how to manufacture proteins that set off immune defenses.
Moderna started its early hantavirus vaccine research alongside the U.S. Army Medical Research Institute of Infectious Diseases, and it’s collaborating with the Vaccine Innovation Center at Korea University College of Medicine, according to a company statement cited by Bloomberg. This research kicked off before the Hondius outbreak.
As of May 8, the World Health Organization counted eight reported cases, three of them fatal. Six infections were confirmed in the lab as Andes virus. WHO pegged the global risk as low, but put the risk level for ship passengers and crew at moderate.
“This is a serious incident,” said WHO Director-General Tedros Adhanom Ghebreyesus last week. Despite the tone, WHO still rates the public health risk as low. Even so, Tedros cautioned that, considering the incubation period, additional cases might still emerge. World Health Organization
Reuters said Monday that two evacuees from the ship tested positive: a French national in worsening condition and an American with only mild symptoms. The remaining 24 passengers were preparing to disembark near Tenerife. WHO continues to call for a 42-day quarantine for those leaving the vessel.
The investment angle looks weak at this point. Moderna’s project is still in its early days, and with no targeted antiviral or vaccine for Andes virus—at least according to the U.S. Centers for Disease Control and Prevention—even a sharp move in the stock on outbreak news might not last if health authorities manage to keep things under control.
Acting CDC Director Jay Bhattacharya distanced the present situation from the pandemic era, telling CNN, as reported by Reuters, “This is not COVID.” He also noted that U.S. passengers would have the option to isolate at home or at a Nebraska facility. Reuters
Moderna is in focus following a first quarter that outpaced forecasts. Revenue jumped to $389 million, more than three times last year’s figure. Almost 80% of that came from outside the U.S. Chief Financial Officer Jamey Mock told Reuters the U.S. COVID market should stabilize by 2026.
The company is making another move into flu. In a late-stage study involving over 40,000 adults aged 50 and up, its mRNA seasonal flu shot topped conventional vaccines—researchers say it beat GSK’s standard-dose flu vaccine by 26.6% for effectiveness.
Investors might be eyeing a bigger hurdle beyond infectious disease. “Near-term, things appear to have stabilized,” Bernstein’s Courtney Breen told Reuters following Moderna’s earnings. Breen noted that focus will move toward the company’s “ex-COVID opportunity in oncology.” Moderna, for its part, is working with Merck on a personalized cancer vaccine. Reuters
Monday’s hantavirus trade ends up serving as a modest nudge about Moderna’s platform rather than signaling any kind of fresh revenue source. There’s a research pitch from the company. Public health officials, for their part, wrestle with containment. And investors circle back to the same old question: how much of Moderna’s post-COVID narrative is actual product, and how much is just promise.
